Search Results - "OLANOW, C"

Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion-Like Disorder? by Olanow, C. Warren, Brundin, Patrik

“…ABSTRACT Altered protein handling is thought to play a key role in the etiopathogenesis of Parkinson's disease (PD), as the disorder is characterized…”
Get full text

Levodopa: A new look at an old friend by Olanow, C. Warren, Stocchi, Fabrizio

“…ABSTRACT Levodopa is the most effective antiparkinsonian agent, but chronic treatment is associated with the development of motor complications in the majority…”
Get full text

Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less by Olanow, C. Warren

Get full text

Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities by Olanow, C. Warren, Calabresi, Paolo, Obeso, Jose A.

“…Levodopa‐induced motor complications remain an important source of disability for many patients with Parkinson's disease. Substantial laboratory evidence…”
Get full text

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease by KORDOWER, Jeffrey H, WARREN OLANOW, C, DODIYA, Hemraj B, YAPING CHU, BEACH, Thomas G, ADLER, Charles H, HALLIDAY, Glenda M, BARTUS, Raymond T

“…The pace of nigrostriatal degeneration, both with regards to striatal denervation and loss of melanin and tyrosine hydroxylase-positive neurons, is poorly…”
Get full text

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity by Werner, Milton H., Olanow, C. Warren

“…ABSTRACT Parkinson's disease (PD) is the second most prevalent neurodegenerative disease of the central nervous system, with an estimated 5 000 000 cases…”
Get full text

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives by Schapira, Anthony H V, Prof, Olanow, C Warren, Prof, Greenamyre, J Timothy, Prof, Bezard, Erwan, Prof

“…Summary Several important advances have been made in our understanding of the pathways that lead to cell dysfunction and death in Parkinson's disease and…”
Get full text

Temporal evolution of microglia and α-synuclein accumulation following foetal grafting in Parkinson's disease by Olanow, C Warren, Savolainen, Mari, Chu, Yaping, Halliday, Glenda M, Kordower, Jeffrey H

“…We observed Lewy pathology in healthy embryonic dopamine neurons implanted into the striatum of patients with advanced Parkinson's disease. In the present…”
Get full text

The scientific and clinical basis for the treatment of Parkinson disease (2009) by OLANOW, C. Warren, STERN, Matthew B, SETHI, Kapil

“…Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many as 1-2% of persons aged 60 years and older. With the aging of the…”
Get full text

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease by Warren Olanow, C., Kieburtz, Karl, Rascol, Olivier, Poewe, Werner, Schapira, Anthony H., Emre, Murat, Nissinen, Helena, Leinonen, Mika, Stocchi, Fabrizio

“…ABSTRACT The Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE‐PD) study compared the initiation of levodopa (l‐dopa) therapy with…”
Get full text

Manganese-Induced Parkinsonism and Parkinson's Disease by Olanow, C W.

“…: It has long been appreciated that manganese exposure can cause neurotoxicity and a neurologic syndrome that resembles Parkinson's disease (PD). Current…”
Get full text

On‐Demand Therapy for OFF Episodes in Parkinson's Disease by Olanow, C. Warren, Poewe, Werner, Rascol, Olivier, Stocchi, Fabrizio

“…ABSTRACT Levodopa is the most effective therapy for Parkinson's disease; however, chronic treatment is associated with the development of OFF episodes, in…”
Get full text

Huntington's disease: Current and future therapeutic prospects by Kieburtz, Karl, Reilmann, Ralf, Olanow, C. Warren

“…ABSTRACT Huntington's disease is a progressive neurodegenerative disorder for which therapies are woefully inadequate and do not prevent inevitable…”
Get full text

Levodopa: Effect on cell death and the natural history of Parkinson's disease by Olanow, C. Warren

“…ABSTRACT This review article considers the question of whether or not levodopa is toxic in Parkinson's disease (PD). l‐dopa is the most effective symptomatic…”
Get full text

Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease by Chu, Yaping, Bartus, Raymond T, Manfredsson, Fredric P, Olanow, C Warren, Kordower, Jeffrey H

“…We performed post-mortem studies on two patients with advanced Parkinson's disease 8 and10 years following AAV2-neurturin (CERE120) gene therapy, the longest…”
Get full text

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients by Bartus, Raymond T, Baumann, Tiffany L, Siffert, Joao, Herzog, Christopher D, Alterman, Ron, Boulis, Nicholas, Turner, Dennis A, Stacy, Mark, Lang, Anthony E, Lozano, Andres M, Olanow, C Warren

“…OBJECTIVE:In an effort to account for deficiencies in axonal transport that limit the effectiveness of neurotrophic factors, this study tested the safety and…”
Get full text

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations by Dehay, Benjamin, PhD, Bourdenx, Mathieu, MS, Gorry, Philippe, MD, Przedborski, Serge, Prof, Vila, Miquel, MD, Hunot, Stéphane, PhD, Singleton, Andrew, PhD, Olanow, C Warren, Prof, Merchant, Kalpana M, PhD, Bezard, Erwan, Prof, Petsko, Gregory A, Prof, Meissner, Wassilios G, Prof

“…Summary Progressive neuronal cell loss in a small subset of brainstem and mesencephalic nuclei and widespread aggregation of the α-synuclein protein in the…”
Get full text

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study by Olanow, C Warren, Prof, Kieburtz, Karl, MD, Odin, Per, MD, Espay, Alberto J, MD, Standaert, David G, MD, Fernandez, Hubert H, MD, Vanagunas, Arvydas, MD, Othman, Ahmed A, PhD, Widnell, Katherine L, MD, Robieson, Weining Z, PhD, Pritchett, Yili, PhD, Chatamra, Krai, PhD, Benesh, Janet, BSMT, Lenz, Robert A, MD, Antonini, Angelo, MD

“…Summary Background Levodopa is the most effective therapy for Parkinson's disease, but chronic treatment is associated with the development of potentially…”
Get full text

The pathogenesis of cell death in Parkinson's disease - 2007 by Olanow, C. Warren

“…A number of factors have been implicated in the pathogenesis of cell death in Parkinson's disease (PD). These include oxidative stress, mitochondrial…”
Get full text

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial by Warren Olanow, C., Bartus, Raymond T., Baumann, Tiffany L., Factor, Stewart, Boulis, Nicholas, Stacy, Mark, Turner, Dennis A., Marks, William, Larson, Paul, Starr, Phillip A., Jankovic, Joseph, Simpson, Richard, Watts, Ray, Guthrie, Barton, Poston, Kathleen, Henderson, Jaimie M., Stern, Matthew, Baltuch, Gordon, Goetz, Christopher G., Herzog, Christopher, Kordower, Jeffrey H., Alterman, Ron, Lozano, Andres M., Lang, Anthony E.

“…Objective A 12‐month double‐blind sham‐surgery–controlled trial assessing adeno‐associated virus type 2 (AAV2)‐neurturin injected into the putamen bilaterally…”
Get full text